Both of these are topical calcineurin inhibitors — non-steroid creams that calm eczema by blocking one specific immune pathway in the skin.
They came out around the same time and are prescribed for the same reasons: eczema on delicate skin, and long-term control without the thinning that steroids cause.
The difference between them is largely one of degree.
These two are nearly identical on the grid, which is the point — same inflammation mechanism, same protection of the barrier and pigment rows that steroids cost you. The only real variable is potency, and it runs in the expected direction: tacrolimus is stronger and stings more, pimecrolimus is milder and easier to keep using. Nothing here touches pore, dermis, or antioxidant function.
Moderate to severe eczema | Protopic | Strong
Tacrolimus is the stronger molecule and performs better on more active disease. Indirect comparisons consistently place tacrolimus 0.1% ahead of pimecrolimus 1%.
Mild eczema | Elidel | Moderate
When inflammation is mild, the extra strength is not needed and the extra sting is not worth it.
Children | Elidel, often | Moderate
Better tolerated and less likely to be abandoned. Both are approved down to age 2.
Face and eyelids | Either | Consensus
Both are safe here, which is their main advantage over steroids. Choose by severity.
Comfort on application | Elidel | Consensus
Tacrolimus burns or stings noticeably in the first few days for many people. Pimecrolimus stings less.
Texture | Elidel | —
A light cream, versus a greasy ointment. This matters more than it sounds for daily adherence, especially on the face.
Skin of color | Either | Consensus
Neither causes the lightening that steroids can, which is their shared advantage on deeper skin tones.
Cost and availability | Roughly equal | —
Both have generics now. Coverage varies by plan more than by drug.
Pick one. Using both adds nothing — they work on the same pathway.
Choose tacrolimus if: eczema is moderate or stubborn, or pimecrolimus has not been strong enough. Use the 0.1% for adults and 0.03% for children.
Choose pimecrolimus if: eczema is mild, it is for a child, it is on the face, or you tried tacrolimus and could not tolerate the burning.
Switching between them is normal and worth doing rather than giving up on the whole category.
Both are maintenance drugs. The best evidence for either is using them two or three times a week on the spots that always flare — not just reactively when things are already bad.
Both still need a steroid sometimes. Neither is fast enough to settle a bad flare on its own. A short steroid burst followed by one of these is the standard sequence.
Both carry the same boxed warning about a theoretical cancer risk. Long-term data have not confirmed a real-world increase, and both remain recommended by dermatology guidelines — but it is a reasonable thing to raise with your own doctor.